Analysis of Ferroptosis-Related Gene Expression and Prognostic Factors of Renal Clear Cell Carcinoma Based on TCGA Database

References

• Akhtar M, Al-Bozom IA, Al Hussain T. Molecular and metabolic basis of clear cell carcinoma of the kidney. Adv Anat Pathol. 2018;25(3):189–196. doi:10.1097/PAP.0000000000000185
   PubMed Web of Science ®Google Scholar
• Luo Y, Shen D, Chen L, et al. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma. Aging. 2019;11(16):6029–6052. doi:10.18632/aging.102161
   PubMedGoogle Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.
   PubMed Web of Science ®Google Scholar
• Inamura K. Renal cell tumors: understanding their molecular pathological epidemiology and the 2016 WHO classification. Int J Mol Sci. 2017;18(10):2195. doi:10.3390/ijms18102195
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924. doi:10.1016/j.eururo.2015.01.005
   PubMed Web of Science ®Google Scholar
• Petejova N, Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):183–194. doi:10.5507/bp.2015.050
   PubMed Web of Science ®Google Scholar
• Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17(7):1355–1364. doi:10.1158/1535-7163.MCT-17-1299
   PubMed Web of Science ®Google Scholar
• Xu WH, Xu Y, Wang J, et al. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging. 2019;11(17):6999–7020. doi:10.18632/aging.102233
   PubMedGoogle Scholar
• Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 2019;31(51):e1904197. doi:10.1002/adma.201904197
   PubMed Web of Science ®Google Scholar
• Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med. 2019;133:130–143. doi:10.1016/j.freeradbiomed.2018.09.043
   PubMed Web of Science ®Google Scholar
• Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. doi:10.1186/s13045-019-0720-y
   PubMed Web of Science ®Google Scholar
• Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830–849. doi:10.1016/j.ccell.2019.04.002
   PubMed Web of Science ®Google Scholar
• Bebber CM, Müller F, Prieto Clemente L, Weber J, von Karstedt S. Ferroptosis in cancer cell biology. Cancers. 2020;12(1):164. doi:10.3390/cancers12010164
   PubMed Web of Science ®Google Scholar
• Tang S, Xiao X. Ferroptosis and kidney diseases. Int Urol Nephrol. 2020;52(3):497–503. doi:10.1007/s11255-019-02335-7
   PubMed Web of Science ®Google Scholar
• Mou Y, Wu J, Zhang Y, Abdihamid O, Duan C, Li B. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma. BMC Cancer. 2021;21(1):18. doi:10.1186/s12885-020-07726-z
   PubMed Web of Science ®Google Scholar
• Liang JY, Wang DS, Lin HC, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Int J Biol Sci. 2020;16(13):2430–2441. doi:10.7150/ijbs.45050
   PubMed Web of Science ®Google Scholar
• Liu HJ, Hu HM, Li GZ, et al. Ferroptosis-related gene signature predicts glioma cell death and glioma patient progression. Front Cell Dev Biol. 2020;8:538. doi:10.3389/fcell.2020.00538
   PubMed Web of Science ®Google Scholar
• Jiang Y, Mao C, Yang R, et al. EGLN1/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics. 2017;7(13):3293–3305. doi:10.7150/thno.19988
   PubMed Web of Science ®Google Scholar
• Wang Y, Yin C, Geng L, Cai W. Immune infiltration landscape in clear cell renal cell carcinoma implications. Front Oncol. 2020;10:491621. doi:10.3389/fonc.2020.491621
   PubMed Web of Science ®Google Scholar
• Zeng CM, Chang LL, Ying MD, et al. Aldo-keto reductase AKR1C1-AKR1C4: functions, regulation, and intervention for anti-cancer therapy. Front Pharmacol. 2017;8:119. doi:10.3389/fphar.2017.00119
   PubMed Web of Science ®Google Scholar
• Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79(8):1913–1924. doi:10.1158/0008-5472.CAN-18-3037
   PubMed Web of Science ®Google Scholar
• Lee YM, Kim JM, Lee HJ, Seong IO, Kim KH. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas. Urol Oncol. 2019;37(10):742–748. doi:10.1016/j.urolonc.2019.04.017
   PubMed Web of Science ®Google Scholar
• Benetti A, Martins FL, Sene LB, et al. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD. Am J Physiol Renal Physiol. 2021;320(3):F285–F296. doi:10.1152/ajprenal.00288.2020
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhu S, Song X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 2017;20(7):1692–1704. doi:10.1016/j.celrep.2017.07.055
   PubMed Web of Science ®Google Scholar
• Song X, Xie Y, Kang R, et al. FANCD2 protects against bone marrow injury from ferroptosis. Biochem Biophys Res Commun. 2016;480(3):443–449. doi:10.1016/j.bbrc.2016.10.068
   PubMed Web of Science ®Google Scholar
• Maleckaite R, Zalimas A, Bakavicius A, Jankevicius F, Jarmalaite S, Daniunaite K. DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma. Oncol Rep. 2019;41(6):3535–3544.
   PubMed Web of Science ®Google Scholar
• Ding C, Ding X, Zheng J, et al. miR-182-5p and miR-378a-3p regulate ferroptosis in I/R-induced renal injury. Cell Death Dis. 2020;11(10):929. doi:10.1038/s41419-020-03135-z
   PubMed Web of Science ®Google Scholar
• Lin W, Wang C, Liu G, et al. SLC7A11/xCT in cancer: biological functions and therapeutic implications. Am J Cancer Res. 2020;10(10):3106–3126.
   PubMed Web of Science ®Google Scholar
• Wang J, Papanicolau-Sengos A, Chintala S, et al. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget. 2016;7(21):29901–29915. doi:10.18632/oncotarget.9093
   PubMedGoogle Scholar
• Wu G, Wang Q, Xu Y, Li Q, Cheng L. A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma. Aging. 2020;12(14):14933–14948. doi:10.18632/aging.103553
   PubMedGoogle Scholar
• Stockwell BR, Jiang X. A physiological function for ferroptosis in tumor suppression by the immune system. Cell Metab. 2019;30(1):14–15. doi:10.1016/j.cmet.2019.06.012
   PubMed Web of Science ®Google Scholar
• Qi Y, Xia Y, Lin Z, et al. Tumor-infiltrating CD39(+)CD8(+) T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. Cancer Immunol Immunother. 2020;69(8):1565–1576. doi:10.1007/s00262-020-02563-2
   PubMed Web of Science ®Google Scholar
• Lin J, Yu M, Xu X, et al. Identification of biomarkers related to CD8(+) T cell infiltration with gene co-expression network in clear cell renal cell carcinoma. Aging. 2020;12(4):3694–3712. doi:10.18632/aging.102841
   PubMedGoogle Scholar
• An HJ, Koh HM, Lee JS, Song DH. Prognostic role of macrophage migration inhibitory factor in patients with clear cell renal cell carcinoma. Medicine. 2020;99(50):e23277. doi:10.1097/MD.0000000000023277
   PubMed Web of Science ®Google Scholar
• Guan X, Liu Z, Zhang J, Jin X. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors. Adv Clin Exp Med. 2018;27(7):947–953. doi:10.17219/acem/70065
   PubMed Web of Science ®Google Scholar
• Wang Y, Su J, Wang Y, et al. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis. J Exp Clin Cancer Res. 2019;38(1):386. doi:10.1186/s13046-019-1347-0
   PubMed Web of Science ®Google Scholar
• Ma YL, Chen F, Shi J. Rhein inhibits malignant phenotypes of human renal cell carcinoma by impacting on MAPK/NF-κB signaling pathways. Onco Targets Ther. 2018;11:1385–1394. doi:10.2147/OTT.S153798
   PubMed Web of Science ®Google Scholar